This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caballero, A. E. Articles by Rull, J. A. Search for Related Content PubMed PubMed Citation Articles by Caballero, A. E. Articles by Rull, J. A.

The Differential Effects of Metformin on Markers of Endothelial Activation and Inflammation in Subjects with Impaired Glucose Tolerance: A Placebo-Controlled, Randomized Clinical Trial

Clinical Research Center (A.E.C.), Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02215; and Departments of Endocrinology and Metabolism (A.D., C.A.A.-S., A.N.H., J.L.C., F.J.G.-P.), Radiology (T.C.), and Medicine (J.A.R.), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan 14000, Mexico City, Mexico

Address all correspondence and requests for reprints to: Carlos A. Aguilar-Salinas, M.D., Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga Number 15, Tlalpan 14000, Mexico City, Mexico. E-mail: caguilarsalinas{at}yahoo.com.

The effect of metformin (1000 mg twice a day) on markers of endothelial activation, inflammation, and coagulation was investigated in subjects with impaired glucose tolerance (IGT) in a 16-wk, randomized, placebo-controlled, double-blind study. Soluble intercellular adhesion molecule, soluble vascular cell adhesion molecule, C-reactive protein, TNF, von Willebrand factor, and tissue plasminogen activator were measured at baseline and at the end of the trial. Subjects with IGT (n = 55, 14 males and 41 females), aged 48.4 ± 9.6 yr with a body mass index of 31.4 ± 5.6 kg/m², were studied. All participants followed a 1-month stabilization period in their diet and physical activity. Afterward, 29 subjects were assigned to the treatment group and 26 to the control group. A significant reduction in weight, fasting plasma glucose, soluble intercellular adhesion molecule (306 ± 75 vs. 268 ± 61 ng/ml, P = 0.029), soluble vascular cell adhesion molecule (595 ± 114 vs. 508 ± 126 ng/ml, P = 0.006), and von Willebrand factor (124 ± 34 vs. 94 ± 34%, P = 0.001) was seen in the treatment group, whereas tissue plasminogen activator, TNF, and C-reactive protein levels did not change. No change was seen in the control group. Thus, metformin improves the plasma levels of some markers of endothelial activation and coagulation in subjects with IGT, whereas it has no effect on markers of inflammation.

This work was supported by a grant from Silanes Laboratories through FunSalud, a nonprofit health care organization in Mexico.

Abbreviations: A1c, Hemoglobin A_1C; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; FPG, fasting plasma glucose; HDL, high-density lipoprotein; HOMA, homeostasis model of assessment; IGT, impaired glucose tolerance; IR, insulin resistance; LDL, low-density lipoprotein; PAI-1, plasminogen-activator inhibitor 1; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule; tPA, tissue plasminogen activator; vWF, von Willebrand factor.

This article has been cited by other articles:

				A. D. Pradhan, B. M. Everett, N. R. Cook, N. Rifai, and P. M Ridker Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial JAMA, September 16, 2009; 302(11): 1186 - 1194. [Abstract] [Full Text] [PDF]

				R. B. Goldberg Cytokine and Cytokine-Like Inflammation Markers, Endothelial Dysfunction, and Imbalanced Coagulation in Development of Diabetes and Its Complications J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3171 - 3182. [Abstract] [Full Text] [PDF]

				N. Nath, M. Khan, M. K. Paintlia, M. N. Hoda, and S. Giri Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis J. Immunol., June 15, 2009; 182(12): 8005 - 8014. [Abstract] [Full Text] [PDF]

				M. Lilly and M. Godwin Treating prediabetes with metformin: Systematic review and meta-analysis Can Fam Physician, April 1, 2009; 55(4): 363 - 369. [Abstract] [Full Text] [PDF]

				A. Kooy, J. de Jager, P. Lehert, D. Bets, M. G. Wulffele, A. J. M. Donker, and C. D. A. Stehouwer Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus Arch Intern Med, March 23, 2009; 169(6): 616 - 625. [Abstract] [Full Text] [PDF]

				P. Dandona Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein Mayo Clin. Proc., March 1, 2008; 83(3): 333 - 342. [Abstract] [Full Text] [PDF]

				G. Perriello, S. Pampanelli, P. Brunetti, C. D. Pietro, and S. Mariz Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 226 - 230. [Abstract] [PDF]

				T. Persico, V. Savasi, E. Ferrazzi, M. Oneta, A.E. Semprini, and G. Simoni Detection of human immunodeficiency virus-1 RNA and DNA by extractive and in situ PCR in unprocessed semen and seminal fractions isolated by semen-washing procedure Hum. Reprod., June 1, 2006; 21(6): 1525 - 1530. [Abstract] [Full Text] [PDF]

				E. Diamanti-Kandarakis, T. Paterakis, K. Alexandraki, C. Piperi, A. Aessopos, I. Katsikis, N. Katsilambros, G. Kreatsas, and D. Panidis Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin Hum. Reprod., June 1, 2006; 21(6): 1426 - 1431. [Abstract] [Full Text] [PDF]

				Y. Hattori, K. Suzuki, S. Hattori, and K. Kasai Metformin Inhibits Cytokine-Induced Nuclear Factor {kappa}B Activation Via AMP-Activated Protein Kinase Activation in Vascular Endothelial Cells Hypertension, June 1, 2006; 47(6): 1183 - 1188. [Abstract] [Full Text] [PDF]

				K. Isoda, J. L. Young, A. Zirlik, L. A. MacFarlane, N. Tsuboi, N. Gerdes, U. Schonbeck, and P. Libby Metformin Inhibits Proinflammatory Responses and Nuclear Factor-{kappa}B in Human Vascular Wall Cells Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 611 - 617. [Abstract] [Full Text] [PDF]